InMode Ltd. (INMD)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below required floor of 3) — hard block on any new bullish entry; the chart also offers no qualifying long setup (technicalScore 2 < 3 required; price below all key MAs, MACD -0.21 < 0, ADX 35 downtrend), so neither a pullback-limit nor a breakout-stop entry can be advanced.
Company overview
InMode Ltd. is a medical technology company specializing in aesthetic devices, offering both minimally invasive and non-surgical solutions. The company's products utilize advanced radiofrequency technologies for procedures like liposuction, skin firming, and body sculpting. InMode also provides non-invasive products for cosmetic concerns such as hair removal and skin revitalization.
Fundamental
fairInMode's strong financial position contrasts with margin pressure and uncertain demand recovery.
InMode presents a mixed picture with unusually strong financial cushions: debt-free, about $501M in cash and investments (net cash roughly half of market cap), roughly $85-90M of annual free cash flow, and a valuation near 11x trailing earnings, about 5x EV/EBITDA and a 10.8% free-cash-flow yield. Revenue has stabilized in 2026 after two years of decline, but gross and operating margins have reset sharply lower and management expects continued margin pressure; heavy buybacks and a live review of unsolicited takeover interest are the main positives, against open litigation and high share-price volatility.
Sentiment
weakSentiment is muted with no active takeover interest and limited media and retail engagement.
Dominant narrative: the July takeover premium has lapsed — Steel Partners' unsolicited $16.75/share cash bid (announced) expired mid-September, and no forward bullish driver replaces it (next marker is the neutral Q3 print on 2026-10-28). The sentiment delta is determinate and softening — from +0.23 (baseline) to -0.04 (scoring) — with no market-rewarded bullish catalyst in-window and no Red-Flag Screen flags fired; the setup reads weak and driver-less.
Technical
weakThe stock shows a declining trend with price below key moving averages and no bullish triggers.
technicalScore 2 — mostly neutral-to-weak-bearish, bounce-only at best: price 14.13 trades below SMA20 (14.45), SMA50 (14.84), SMA200 (14.39), EMA9 (14.21), EMA21 (14.41), WMA9 (14.15) and WMA21 (14.31); RSI14 33.27 near-oversold; MACD -0.21/-0.19 with histogram -0.02 (contracting); ADX14 35.10 and rising in a declining tape; ATR14 0.19 (1.34% of price) — a low-volatility grind with only faint stabilization (DEMA14 14.06 / TEMA14 14.03 just below price). No tradable long setup; action blocked upstream by the qualitative override (qualitativeScore 2 < 3).
You’re looking at 2026-10-06 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

